Compounds > norbolethone
Page last updated: 2024-12-06

norbolethone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Norbolethone is a synthetic anabolic steroid, structurally similar to testosterone. It was developed in the 1960s and studied for its potential therapeutic uses, including treatment of osteoporosis and anemia. However, it was found to have significant side effects, including liver toxicity and masculinizing effects in women. Despite its anabolic effects, it's not commonly used in clinical practice due to its safety concerns. Research into norbolethone has been limited in recent decades due to its negative side effects and the availability of safer alternative treatments. '

norbolethone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID66255
CHEMBL ID2105134
SCHEMBL ID548124
MeSH IDM0435950

Synonyms (78)

Synonym
wln: l e5 b666 ov mutj e2 fq f2
mls002694957 ,
gon-4-en-3-one,17.alpha.-diethyl-17-hydroxy-
18, 13-ethyl-17-hydroxy-, (17.alpha.)-
nsc-89791
18, 13-ethyl-17-hydroxy-
13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-4-en-3-one
18,19-dinor-17-alpha-pregn-4-en-3-one, 13-ethyl-17-hydroxy-, (+-)-
18,19-dinor-17-alpha-pregn-4-en-3-one, 13-ethyl-17-hydroxy-
norboletonum [inn-latin]
18,19-dinor-17alpha-pregn-4-en-3-one, 13-ethyl-17-hydroxy-
nsc 89791
norboletone [inn]
(+-)-13-ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-3-one
norbolethone [usan]
18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-
norboletona [inn-spanish]
3-ethyl-17-hydroxy-18,19-dinor-pregn-4-en-3-one
(+-)-13-ethyl-17-hydroxy-18,19-dinor-17alpha -pregn-4-en-3-one
dl-13-beta,17-alpha-diethyl-17-beta-hydroxygon-4-en-3-one
18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17alpha)-, (+-)-
dl-norbolethone
genabol
wy 3475
18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-
797-58-0
norbolethone
nsc89791
norbalethone
(.+-.)-13-ethyl-17-hydroxy-18,19-dinor-17.alpha.-pregn-4-en-3-one
wy-3475
18,19-dinor-17.alpha.-pregn-4-en-3-one, 13-ethyl-17-hydroxy-
norbolethone (usan)
1235-15-0
D05204
(8r,9s,10r,13s,14s,17s)-13,17-diethyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
norboletone
13-ethyl-17-hydroxy-18,19-dinor-17-pregn-4-en-20-yn-3-one
norbolethone [usan:inn]
u3bzu2241a ,
unii-u3bzu2241a
13beta,17alpha-diethyl-17beta-hydroxygon-4-en-3-one
CHEMBL2105134
norbolhetone
norboletonum
unii-o60979l83f
norboletona
o60979l83f ,
(17.alpha.)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-3-one
13-ethyl-17-hydroxy-18,19-dinor-17.alpha.-pregn-4-en-3-one
norbolethone d-form [mi]
norboletone, (+)-
norbolethone, (+)-
13,17.alpha.-diethyl-17-hydroxygon-4-en-3-one
d-norbolethone
SCHEMBL548124
FTBJKONNNSKOLX-XUDSTZEESA-N
(+/-)-13-ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-3-one
norbolethone [mi]
norboletone [mart.]
18,19-dinorpregn-4-en-3-one, 13-ethyl-17-hydroxy-, (17.alpha.)-, (+/-)-
13.beta.,17.alpha.-diethyl-17.beta.-hydroxygon-4-en-3-one
DTXSID50154027
(1s,2r,10r,11s,14s,15s)-14,15-diethyl-14-hydroxytetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one
AKOS030253215
(+/-)-13b,17a-diethyl-17b-hydroxygon-4-en-3-one
(17a)-(+/-)-13-ethyl-17-hydroxy-18,19-dinorpregn-4-en-3-one
(+/-)-17a-ethyl-18-homo-19-nortestosterone
dl-17b-hydroxy-13b,17a-diethylgon-4-en-3-one
dl-13,17a-diethyl-17-hydroxygon-4-en-3-one
dl-13,17a-diethyl-17b-hydroxygon-4-en-3-one
(+/-)-13,17a-diethyl-17b-hydroxygon-4-en-3-one
13-ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-3-one
HY-U00108
CS-7144
Q410981
DTXSID801015371
alpha-norbolethone

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's4 (80.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.82 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
norethindrone
Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.		2.041017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		progestin;
synthetic oral contraceptive
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.041017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
gestrinone
Gestrinone: A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.		2.7230oxo steroid
19-norprogesterone
19-norprogesterone: RN given refers to cpd without isomeric designation		2.0410corticosteroid hormone
1-testosterone
Delta(1)-dihydrotestosterone : An anabolic steroid that differs from testosterone by having a 1,2-double bond instead of a 4,5-double bond in its A ring. A potent androgen with anabolic properties, it was legally sold as a prohormone in the U.S.A. until 2005, when it was reclassified as a Schedule III drug.		2.041017beta-hydroxy steroid;
3-oxo-Delta(1) steroid;
anabolic androgenic steroid		anabolic agent
ethisterone
Ethisterone: 17 alpha-Hydroxypregn-4-en-20-yn-3-one. A synthetic steroid hormone with progestational effects.. ethisterone : A 17beta-hydroxy steroid that is testosterone in which the 17beta hydrogen is replaced by an ethynyl group. Ethisterone was the first orally active progestin and is a metabolite of danazol.		2.041017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol		drug metabolite;
progestin
tetrahydrogestrinone
[no description available]		2.04103-hydroxy steroid
norgestrel
Norgestrel: A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0410